Abstracts tagged "B cells"

Abstract Number: 916 • 2013 ACR/ARHP Annual Meeting
Role Of CD20+ B Cells As Antigen-Presenting Cells In Arthritis
Estefania Armas-Gonzalez¹, Ana Diaz-Martin¹, María Jesús Dominguez-Luis¹, Maria Teresa Arce-Franco¹, Ada Herrera-Garcia¹, Vanesa Hernandez¹, Alicia Usategui², Jose L. Pablos³, Sagrario Bustabad¹ and Federico Diaz-Gonzalez⁴, ¹Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ³Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: B cells participate in the pathogenesis of rheumatoid arthritis (RA) through a mechanism still not fully understood. In RA, B cells are believed to…
Abstract Number: 24 • 2013 ACR/ARHP Annual Meeting
Plasma Cells In Acute Systemic Lupus Erythematosus Flares Are Characterized By a Highly Diversified Repertoire Accentuated By Clonal Expansions Of VH4-34 Antibodies
Christopher Tipton¹, Christopher Fucile², Alex Rosenberg², Scott Jenks³, Jennifer Hom⁴, F. Eun-Hyung Lee⁴ and Inaki Sanz¹, ¹Medicine/Rheumatology, Emory University, Atlanta, GA, ²University of Rochester, Rochester, NY, ³Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose :Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which faulty B cell tolerance promotes the generation of multiple autoantibodies of which anti-ds DNA,…
Abstract Number: 2382 • 2013 ACR/ARHP Annual Meeting
B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Anne-Priscille Trouvin¹, Serge Jacquot², Sébastien Grigioni³, Hélène Boulard¹, Ingrid Dutot², Olivier Vittecoq⁴, Xavier Le Loët⁵, Olivier Boyer⁶ and Vincent Goëb⁷, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²INSERM U905, University of Rouen, Rouen, France, ³Pain and Nutrition, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Immunology, INSERM U905, University of Rouen, Rouen, France, ⁷Rheumatology, Amiens University Hospital, Amiens, France
Background/Purpose: Rituximab is a safe and effective treatment in rheumatoid arthritis (RA), however the current treatment regimen requires to wait for a clinical relapse before…
Abstract Number: 917 • 2013 ACR/ARHP Annual Meeting
B-Regulatory-, CD19⁺CD20⁺CD24^highCD38^high -Cells Are Functionally Impaired In Patients With Rheumatoid Arthritis and Healthy First Degree Relatives Compared With Controls
Mikael Brink¹, Kristina Lejon², Lisbeth Ärlestig³ and Solbritt Rantapää Dahlqvist⁴, ¹Rheumatology, Umeå University, Umea, Sweden, ²Clinical Microbiology, Division of Immunology, Umeå Universitet, Umeå, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease with both genetic- and environmental risk factors. By studying first degree relatives (FDR) of RA patients which…
Abstract Number: 30 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiling Analysis Of Human B-Cell Subsets In Health and Systemic Lupus Erythematosus
Chungwen Wei¹, Edward Ramos², Norm Allaire³, Suzanne Szak³, Susan Kalled³, Ann Ranger³ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Biogen Idec Inc, Cambridge, MA
Background/Purpose: SLE is an autoimmune disease, which exhibits multiple B cell abnormalities including expanded populations of plasmablasts and DN memory cells as well as a…
Abstract Number: 1874 • 2013 ACR/ARHP Annual Meeting
Genome-Wide Profiling Identifies Significant Differences Between The T-Lymphocyte and B-Lymphocyte Methylomes In Healthy Individuals
John Glossop^1,2, Nicola Nixon², Richard Emes³, Kim Haworth¹, Jonathon Packham², Peter Dawes², Anthony Fryer¹, Derek Mattey^1,2 and William Farrell¹, ¹Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, United Kingdom, ²Rheumatology, Haywood Rheumatology Centre, Stoke-on-Trent, United Kingdom, ³School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, United Kingdom
Background/Purpose: Multiple reports now describe changes to the DNA methylome in a variety of autoimmune disorders, such as rheumatoid arthritis. In many cases, these studies…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 1867 • 2013 ACR/ARHP Annual Meeting
Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation
Julia Sieber¹, Capucine Daridon², Simon Fillatreau³ and Thomas Dörner¹, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ³German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany
Background/Purpose: Beyond their antibody producing function, B cells have been shown to be potent antigen-presenting and cytokine-producing cells. In systemic lupus erythematosus (SLE), B cells…
Abstract Number: 919 • 2013 ACR/ARHP Annual Meeting
B Cell Derived IFN-γ Contributes To The Negative Regulation Of T-Regulatory Cell Differentiation In Arthritis
Susan Olalekan¹, Yanxia Cao² and Alison Finnegan², ¹Immunology, Rush University Medical Center, Chicago, IL, ²Dept of Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: Depletion of B cells using a monoclonal antibody against CD20 expressed on mature B cells has proven efficacious in patients with rheumatoid arthritis (RA).…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Rohit Aggarwal¹, Chester V. Oddis², Erich R Wilkerson³, Diane Koontz⁴, Ilinca D. Metes⁵, Ann M. Reed⁶, Dana P. Ascherman⁷ and Marc C. Levesque⁸, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting
Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Mattias Svensson¹, Kersti Månsson¹, Karin Andersson¹, Mats Bemark², Mikael Brisslert¹ and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
MC Genovese¹, Gregg J. Silverman², Paul Emery³, Ramesh Gupta⁴, Anne Gill⁵, Wendy J. Komocsar⁵, Melissa Veenhuizen⁵, Li Xie⁵, Pierre-Yves Berclaz⁵ and Chin Lee⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology, NYU School of Medicine, New York, NY, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Private Practice, Memphis, TN, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].